Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Overcoming Acquired Resistance With Second-Generation TRK Inhibitors

In this podcast episode, listen to George D. Demetri, MD, and Alexander Drilon, MD, discuss emerging data on the efficacy, safety, and clinical role of second-generation TRK inhibitors that can overcome acquired resistance to currently approved TRK inhibitors.
George D. Demetri, MD
Alexander Drilon, MD
Released: November 9, 2021

In this podcast episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss emerging data on the efficacy, safety, and clinical role of second-generation TRK inhibitors that can overcome acquired resistance to first-generation agents in NTRK fusion–positive solid tumors. Topics include:

  • Mechanisms of acquired resistance to TRK inhibitor therapy
  • Clinical trial data on the second-generation inhibitors selitrectinib and repotrectinib
  • Safety profiles of first- vs second-generation TRK inhibitors

Information on this Educational Activity

Faculty

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

George D. Demetri, MD, has disclosed that he has received funds for research support and consulting fees from Bayer, Ignyta, Loxo, and Roche, and serves as a member of the board of directors for Blueprint Medicines.
Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has disclosed that he has received consulting fees from 14ner/Elevation Oncology, AbbVie, ArcherDX, AstraZeneca, AXIS, BeiGene, BergenBio, Blueprint Medicines, EMD Serono, Exelixis, Helsinn, Hengrui, Ignyta/Genentech/Roche, Liberum, Loxo/Bayer/Lilly, Melendi, Merus, Monopteros, MORE Health, Novartis, Nuvalent, Pfizer, Remedica, Repare RX, Takeda/Ariad/Millennium, TP Therapeutics, Tyra Biosciences, and Verastem; funds for research support from Exelixis, Foundation Medicine GlaxoSmithKline, Pfizer, PharmaMar, Taiho, and Teva; and other financial support or material from Boehringer Ingelheim, Merck, Merus, and Puma.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Downloadable powerpoint slideset with key takeways on the use of immune checkpoint inhibitors for resectable early-stage NSCLC, from Clinical Care Options (CCO)

Justin F. Gainor, MD
Program Director
Released: January 18, 2022

Free video from Clinical Care Options (CCO) featuring expert discussion of the latest updates in immunotherapy for early-stage NSCLC

Justin F. Gainor, MD
Program Director
Stephen V. Liu, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 10, 2022 Expired: January 9, 2023

Experts discuss best practices in managing patients with hepatocellular carcinoma (HCC), from Clinical Care Options (CCO)

Richard S. Finn, MD Amit G. Singal, MD, MS Mark Yarchoan, MD Released: January 3, 2022

Drs Enriqueta Felip and Alexander Spira discuss the emerging role of EGFR exon 20 insertion mutations in the management of advanced NSCLC, from Clinical Care Options (CCO)

Enriqueta Felip, MD Alexander Spira, MD, PhD, FACP Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: December 28, 2021 Expired: December 27, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings